

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
12 November 2020 (12.11.2020)



(10) International Publication Number
WO 2020/227101 A1

(51) International Patent Classification:

A61K 31/4245 (2006.01) C07D 213/56 (2006.01)
A61K 31/16 (2006.01) C07D 231/02 (2006.01)
A61K 31/415 (2006.01) C07D 271/06 (2006.01)

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2020/031046

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(22) International Filing Date:

01 May 2020 (01.05.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/842,849 03 May 2019 (03.05.2019) US
62/982,864 28 February 2020 (28.02.2020) US

(71) Applicant: PRAXIS PRECISION MEDICINES, INC.

[US/US]; One Broadway 16th Floor, Cambridge, MA
02142 (US).

(72) Inventors: MARTINEZ BOTELLA, Gabriel; 17 Par-

menter Road, Wayland, MA 01778 (US). GRIFFIN, An-
drew, Mark; 232 Rue Barette, L'île Bizard, QC H9C2Y
(CA). CHARIFSON, Paul, S.; 7 Dartmouth Drive, Fram-
ingham, MA 01701 (US). REDDY, Kiran; 14 9th Street,
Unit 14, Boston, MA 02129 (US). KAHLIG, Michael
Kristopher, Mathieu; 1130 James Avenue, Redwood City,
CA 94062 (US). MARRON, Brian, Edward; 1955 Augus-
ta Valley Ln SE, Ada, MI 49301 (US).

(74) Agent: CHOI, Boyeon et al.; Goodwin Procter LLP,

100 Northern Avenue, IP DOCKETING DEPT./7TH FL.,
Boston, MA 02210 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: KCNT1 INHIBITORS AND METHODS OF USE

(57) Abstract: The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neu-
rological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in
a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal
excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

WO 2020/227101 A1